Literature DB >> 26056160

A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude).

Harriet Hammer1, Benjamin M Bader1, Corina Ehnert1, Christoffer Bundgaard1, Lennart Bunch1, Kirsten Hoestgaard-Jensen1, Olaf H-U Schroeder1, Jesper F Bastlund1, Alexandra Gramowski-Voß1, Anders A Jensen2.   

Abstract

In the present study, we have elucidated the functional characteristics and mechanism of action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s-1970s. Methaqualone was demonstrated to be a positive allosteric modulator at human α1,2,3,5β2,3γ2S GABAA receptors (GABAARs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the α4,6β1,2,3δ GABAAR subtypes, ranging from inactivity (α4β1δ), through negative (α6β1δ) or positive allosteric modulation (α4β2δ, α6β2,3δ), to superagonism (α4β3δ). Methaqualone did not interact with the benzodiazepine, barbiturate, or neurosteroid binding sites in the GABAAR. Instead, the compound is proposed to act through the transmembrane β((+))/α((-)) subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate. The negligible activities displayed by methaqualone at numerous neurotransmitter receptors and transporters in an elaborate screening for additional putative central nervous system (CNS) targets suggest that it is a selective GABAAR modulator. The mode of action of methaqualone was further investigated in multichannel recordings from primary frontal cortex networks, where the overall activity changes induced by the compound at 1-100 μM concentrations were quite similar to those mediated by other CNS depressants. Finally, the free methaqualone concentrations in the mouse brain arising from doses producing significant in vivo effects in assays for locomotion and anticonvulsant activity correlated fairly well with its potencies as a modulator at the recombinant GABAARs. Hence, we propose that the multifaceted functional properties exhibited by methaqualone at GABAARs give rise to its effects as a therapeutic and recreational drug.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26056160      PMCID: PMC4518083          DOI: 10.1124/mol.115.099291

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  91 in total

1.  Structural domains of the human GABAA receptor 3 subunit involved in the actions of pentobarbital.

Authors:  R Serafini; J Bracamontes; J H Steinbach
Journal:  J Physiol       Date:  2000-05-01       Impact factor: 5.182

2.  Low nanomolar GABA effects at extrasynaptic α4β1/β3δ GABA(A) receptor subtypes indicate a different binding mode for GABA at these receptors.

Authors:  Nasiara Karim; Petrine Wellendorph; Nathan Absalom; Line Haunstrup Bang; Marianne Lerbech Jensen; Maja Michelle Hansen; Ho Joon Lee; Graham A R Johnston; Jane R Hanrahan; Mary Chebib
Journal:  Biochem Pharmacol       Date:  2012-05-29       Impact factor: 5.858

3.  11-trifluoromethyl-phenyldiazirinyl neurosteroid analogues: potent general anesthetics and photolabeling reagents for GABAA receptors.

Authors:  Zi-Wei Chen; Cunde Wang; Kathiresan Krishnan; Brad D Manion; Randy Hastings; John Bracamontes; Amanda Taylor; Megan M Eaton; Charles F Zorumski; Joseph H Steinbach; Gustav Akk; Steven Mennerick; Douglas F Covey; Alex S Evers
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

4.  The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures.

Authors:  Carmela Parenti; Rita Turnaturi; Giuseppina Aricò; Alexandra Gramowski-Voss; Olaf H-U Schroeder; Agostino Marrazzo; Orazio Prezzavento; Simone Ronsisvalle; Giovanna M Scoto; Giuseppe Ronsisvalle; Lorella Pasquinucci
Journal:  Neuropharmacology       Date:  2013-03-27       Impact factor: 5.250

Review 5.  Treatment for methaqualone dependence in adults.

Authors:  G McCarthy; B Myers; N Siegfried
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

6.  Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus.

Authors:  K A Wafford; M B van Niel; Q P Ma; E Horridge; M B Herd; D R Peden; D Belelli; J J Lambert
Journal:  Neuropharmacology       Date:  2008-08-13       Impact factor: 5.250

7.  Structural basis for potentiation by alcohols and anaesthetics in a ligand-gated ion channel.

Authors:  Ludovic Sauguet; Rebecca J Howard; Laurie Malherbe; Ui S Lee; Pierre-Jean Corringer; R Adron Harris; Marc Delarue
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  A single histidine in GABAA receptors is essential for benzodiazepine agonist binding.

Authors:  H A Wieland; H Lüddens; P H Seeburg
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

9.  Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity.

Authors:  Rooma Desai; Dirk Ruesch; Stuart A Forman
Journal:  Anesthesiology       Date:  2009-10       Impact factor: 7.892

10.  GABA Potency at GABA(A) Receptors Found in Synaptic and Extrasynaptic Zones.

Authors:  Martin Mortensen; Bijal Patel; Trevor G Smart
Journal:  Front Cell Neurosci       Date:  2012-01-20       Impact factor: 5.505

View more
  9 in total

1.  Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents.

Authors:  Visarapu Malathi; Nissi Sharon; Pannala Padmaja; Deepak Lokwani; Saurabh Khadse; Prashant Chaudhari; Atul A Shirkhedkar; Pedavenkatagari Narayana Reddy; Vinod G Ugale
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

2.  α-Hydroxy acid as an aldehyde surrogate: metal-free synthesis of pyrrolo[1,2-a]quinoxalines, quinazolinones, and other N-heterocycles via decarboxylative oxidative annulation reaction.

Authors:  Mayavan Viji; Manjunatha Vishwanath; Jaeuk Sim; Yunjeong Park; Chanhyun Jung; Seohu Lee; Heesoon Lee; Kiho Lee; Jae-Kyung Jung
Journal:  RSC Adv       Date:  2020-10-07       Impact factor: 4.036

3.  Accidental afloqualone intoxication in two dogs.

Authors:  Jin-Ok Ahn; Won-Joung Jaung; Sang-Heum Won; Min-Ok Ryu; Woo-Jin Song; Kee-Ok Jeon; Jin-Young Chung; Hwa-Young Youn
Journal:  J Vet Med Sci       Date:  2017-11-14       Impact factor: 1.267

4.  Ginkgo biloba L. (Ginkgoaceae) Leaf Extract Medications From Different Providers Exhibit Differential Functional Effects on Mouse Frontal Cortex Neuronal Networks.

Authors:  Benjamin M Bader; Konstantin Jügelt; Luise Schultz; Olaf H-U Schroeder
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

5.  Evodiamine Reduces Caffeine-Induced Sleep Disturbances and Excitation in Mice.

Authors:  Yong-Hyun Ko; Kyu-Yeon Shim; Seok-Yong Lee; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2018-09-01       Impact factor: 4.634

Review 6.  Asymmetric Synthesis of Axially Chiral C-N Atropisomers.

Authors:  Patricia Rodríguez-Salamanca; Rosario Fernández; Valentín Hornillos; José M Lassaletta
Journal:  Chemistry       Date:  2022-03-25       Impact factor: 5.020

7.  Functional characterization of GABAA receptor-mediated modulation of cortical neuron network activity in microelectrode array recordings.

Authors:  Benjamin M Bader; Anne Steder; Anders Bue Klein; Bente Frølund; Olaf H U Schroeder; Anders A Jensen
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

8.  New Isoxazolidine-Conjugates of Quinazolinones-Synthesis, Antiviral and Cytostatic Activity.

Authors:  Dorota G Piotrowska; Graciela Andrei; Dominique Schols; Robert Snoeck; Magdalena Grabkowska-Drużyc
Journal:  Molecules       Date:  2016-07-22       Impact factor: 4.411

9.  Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow.

Authors:  G D C Mendis; G Berecki; E Morrisroe; S Pachernegg; M Li; M Varney; P B Osborne; C A Reid; S Halgamuge; S Petrou
Journal:  Sci Rep       Date:  2019-01-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.